|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||62.12 / 118.48|
Are the Baker Brothers selling Seattle Genetics? Biomarin CEO throws shade on Sarepta. TG Therapeutics management adds to its credibility problem.
UnitedHealth becomes the second major healthcare provider to scratch the insulin product from its 2017 medicines roster.
TheStreet's Adam Feuerstein answers reader questions about Sarepta Therapeutics and its newly approved drug Exondys 51 for Duchenne muscular dystrophy.
CHMP Opinion and EU Decision Expected Q3 2017
The squeeze is on these stocks, and they are poised for volatile moves.
Oral Presentations Include Updated Long-Term Data from Extension Study of Brineura™ (Cerliponase Alfa) in Children with CLN2 Disease, and Long-Term Safety and Efficacy Data of Pegvaliase in Adults with PKU
For the third consecutive year, BioMarin ranks in top 10 on list
BioMarin (BMRN) stock was trading sharply higher this morning after Pfizer (PFE) beat out Sanofi (SNY) to purchase Medivation (MDVN).
Overall, this is still a good environment for stock picking.
They're striking while the iron is hottest to raise money, reduce debt.
BioMarin (BMRN) stock is trading lower after the market close after announcing a public offering of common stock.
Trade-Ideas LLC identified Biomarin Pharmaceutical (BMRN) as a post-market leader candidate
That may be the best way to get through the notorious month of August.
BMN 270 is one of the most important drugs in Biomarin's research pipeline and key driver of future revenue and earnings.
Conference call and web-cast to be held Wednesday, July 27th at 4:05pm ET
The Swiss pharmaceuticals company confirms a forecast for full-year sales to increase in the low to mid-single digits, and for earnings per share to grow faster than revenue.
TheStreet highlights 3 stocks pushing the drugs industry higher today.